Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

Daniel El Fassi; J Paul Banga; Jacqueline A Gilbert; Carolyn Padoa; Laszlo Hegedüs; Claus H Nielsen

doi:10.1016/j.clim.2008.09.007

Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

Daniel El Fassi, J Paul Banga, Jacqueline A Gilbert, Carolyn Padoa, Laszlo Hegedüs, Claus H Nielsen

78 Citations (Scopus)

Abstract

Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRAb) levels over that of methimazole monotherapy. Using a bioassay involving Chinese hamster ovary cells transfected with the human thyrotropin receptor, we found that the stimulatory capacity of TRAbs was reduced markedly, by 66+/-22%, upon treatment with rituximab and methimazole for 21 days (p

Original language	English
Journal	Clinical Immunology
Volume	130
Issue number	3
Pages (from-to)	252-8
Number of pages	7
ISSN	1521-6616
DOIs	https://doi.org/10.1016/j.clim.2008.09.007
Publication status	Published - 1 Mar 2009

Access to Document

10.1016/j.clim.2008.09.007

Cite this

@article{236747e32eff4edd85c2b8a00f9f77d7,

title = "Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies",

abstract = "Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRAb) levels over that of methimazole monotherapy. Using a bioassay involving Chinese hamster ovary cells transfected with the human thyrotropin receptor, we found that the stimulatory capacity of TRAbs was reduced markedly, by 66+/-22\%, upon treatment with rituximab and methimazole for 21 days (p",

author = "\{El Fassi\}, Daniel and Banga, \{J Paul\} and Gilbert, \{Jacqueline A\} and Carolyn Padoa and Laszlo Heged{\"u}s and Nielsen, \{Claus H\}",

year = "2009",

month = mar,

day = "1",

doi = "10.1016/j.clim.2008.09.007",

language = "English",

volume = "130",

pages = "252--8",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

AU - El Fassi, Daniel

AU - Banga, J Paul

AU - Gilbert, Jacqueline A

AU - Padoa, Carolyn

AU - Hegedüs, Laszlo

AU - Nielsen, Claus H

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRAb) levels over that of methimazole monotherapy. Using a bioassay involving Chinese hamster ovary cells transfected with the human thyrotropin receptor, we found that the stimulatory capacity of TRAbs was reduced markedly, by 66+/-22%, upon treatment with rituximab and methimazole for 21 days (p

AB - Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRAb) levels over that of methimazole monotherapy. Using a bioassay involving Chinese hamster ovary cells transfected with the human thyrotropin receptor, we found that the stimulatory capacity of TRAbs was reduced markedly, by 66+/-22%, upon treatment with rituximab and methimazole for 21 days (p

UR - https://www.scopus.com/pages/publications/59249093047

U2 - 10.1016/j.clim.2008.09.007

DO - 10.1016/j.clim.2008.09.007

M3 - Journal article

C2 - 18964302

SN - 1521-6616

VL - 130

SP - 252

EP - 258

JO - Clinical Immunology

JF - Clinical Immunology

IS - 3

ER -

Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

Abstract

Access to Document

Other files and links

Fingerprint

Cite this